Anti-angiogenic agent ramucirumab: Meaningful or marginal?

Roopma Wadhwa; Elena Elimova; Hironori Shiozaki; Kazuki Sudo; Mariela A. Blum; Jeannelyn S. Estrella; Qiongrong Chen; Shumei Song; Jaffer A. Ajani

doi:10.1586/14737140.2014.896207

Anti-angiogenic agent ramucirumab: Meaningful or marginal?

Roopma Wadhwa, Elena Elimova, Hironori Shiozaki, Kazuki Sudo, Mariela A. Blum, Jeannelyn S. Estrella, Qiongrong Chen, Shumei Song, Jaffer A. Ajani

Research output: Contribution to journal › Article › peer-review

11 Scopus citations

Abstract

Ramucirumab (IMC-1121B) targets VEGFR-2. Ramucirumab is being investigated in many malignancies including gastric cancer. The Phase III trial in patients with advanced breast cancer failed to improve the primary end point The REGARD trial, a Phase III study, in patients with advanced gastric cancer in the second line setting, had a marginal improvement in overall survival but did not achieve the expected hazard ratio target (of 0.69) and the median duration of therapy with ramucirumab was meager 8 weeks (only 2 weeks longer than the placebo's). Other notable agents in the second line setting are docetaxel and irinotecan. Preliminary results of the RAINBOW trial suggest that ramucirumab may be providing more than marginal advantage. In this review, we briefly summarize the process of angiogenesis and address the emerging cost-benefit issues that surround all newly developed agents including ramucirumab.

Original language	English (US)
Pages (from-to)	367-379
Number of pages	13
Journal	Expert review of anticancer therapy
Volume	14
Issue number	4
DOIs	https://doi.org/10.1586/14737140.2014.896207
State	Published - Apr 2014

Keywords

IMC-1121B
VEGF
advanced gastric cancer
angiogenesis
breast cancer
cost-benefit
ramucirumab

ASJC Scopus subject areas

Oncology
Pharmacology (medical)

Access to Document

10.1586/14737140.2014.896207

Cite this

@article{8d4b1dfe4bf24cc085d1a4cc43d600fb,

title = "Anti-angiogenic agent ramucirumab: Meaningful or marginal?",

abstract = "Ramucirumab (IMC-1121B) targets VEGFR-2. Ramucirumab is being investigated in many malignancies including gastric cancer. The Phase III trial in patients with advanced breast cancer failed to improve the primary end point The REGARD trial, a Phase III study, in patients with advanced gastric cancer in the second line setting, had a marginal improvement in overall survival but did not achieve the expected hazard ratio target (of 0.69) and the median duration of therapy with ramucirumab was meager 8 weeks (only 2 weeks longer than the placebo's). Other notable agents in the second line setting are docetaxel and irinotecan. Preliminary results of the RAINBOW trial suggest that ramucirumab may be providing more than marginal advantage. In this review, we briefly summarize the process of angiogenesis and address the emerging cost-benefit issues that surround all newly developed agents including ramucirumab.",

keywords = "IMC-1121B, VEGF, advanced gastric cancer, angiogenesis, breast cancer, cost-benefit, ramucirumab",

author = "Roopma Wadhwa and Elena Elimova and Hironori Shiozaki and Kazuki Sudo and Blum, {Mariela A.} and Estrella, {Jeannelyn S.} and Qiongrong Chen and Shumei Song and Ajani, {Jaffer A.}",

note = "Funding Information: Supported in part by the grant CA127672 (JAA) by the National Cancer Institute, USA, and donations received from the Caporella, Dallas, Sultan, Park, Smith, Frazier, Oaks, Sultan and Cantu Families, the Schecter Private Foundation, Rivercreek Foundation, Kevin Fund, Myer Fund, Dio Fund, Milrod Fund, and the Multidisciplinary Research Grants provided by the University of Texas M. D. Anderson Cancer Center, Houston, USA. JA Ajani has received grants and honoraria from Lilly/ImClone.",

year = "2014",

month = apr,

doi = "10.1586/14737140.2014.896207",

language = "English (US)",

volume = "14",

pages = "367--379",

journal = "Expert review of anticancer therapy",

issn = "1473-7140",

publisher = "Expert Reviews Ltd.",

number = "4",

}

TY - JOUR

T1 - Anti-angiogenic agent ramucirumab

T2 - Meaningful or marginal?

AU - Wadhwa, Roopma

AU - Elimova, Elena

AU - Shiozaki, Hironori

AU - Sudo, Kazuki

AU - Blum, Mariela A.

AU - Estrella, Jeannelyn S.

AU - Chen, Qiongrong

AU - Song, Shumei

AU - Ajani, Jaffer A.

N1 - Funding Information: Supported in part by the grant CA127672 (JAA) by the National Cancer Institute, USA, and donations received from the Caporella, Dallas, Sultan, Park, Smith, Frazier, Oaks, Sultan and Cantu Families, the Schecter Private Foundation, Rivercreek Foundation, Kevin Fund, Myer Fund, Dio Fund, Milrod Fund, and the Multidisciplinary Research Grants provided by the University of Texas M. D. Anderson Cancer Center, Houston, USA. JA Ajani has received grants and honoraria from Lilly/ImClone.

PY - 2014/4

Y1 - 2014/4

N2 - Ramucirumab (IMC-1121B) targets VEGFR-2. Ramucirumab is being investigated in many malignancies including gastric cancer. The Phase III trial in patients with advanced breast cancer failed to improve the primary end point The REGARD trial, a Phase III study, in patients with advanced gastric cancer in the second line setting, had a marginal improvement in overall survival but did not achieve the expected hazard ratio target (of 0.69) and the median duration of therapy with ramucirumab was meager 8 weeks (only 2 weeks longer than the placebo's). Other notable agents in the second line setting are docetaxel and irinotecan. Preliminary results of the RAINBOW trial suggest that ramucirumab may be providing more than marginal advantage. In this review, we briefly summarize the process of angiogenesis and address the emerging cost-benefit issues that surround all newly developed agents including ramucirumab.

AB - Ramucirumab (IMC-1121B) targets VEGFR-2. Ramucirumab is being investigated in many malignancies including gastric cancer. The Phase III trial in patients with advanced breast cancer failed to improve the primary end point The REGARD trial, a Phase III study, in patients with advanced gastric cancer in the second line setting, had a marginal improvement in overall survival but did not achieve the expected hazard ratio target (of 0.69) and the median duration of therapy with ramucirumab was meager 8 weeks (only 2 weeks longer than the placebo's). Other notable agents in the second line setting are docetaxel and irinotecan. Preliminary results of the RAINBOW trial suggest that ramucirumab may be providing more than marginal advantage. In this review, we briefly summarize the process of angiogenesis and address the emerging cost-benefit issues that surround all newly developed agents including ramucirumab.

KW - IMC-1121B

KW - VEGF

KW - advanced gastric cancer

KW - angiogenesis

KW - breast cancer

KW - cost-benefit

KW - ramucirumab

UR - http://www.scopus.com/inward/record.url?scp=84896941352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896941352&partnerID=8YFLogxK

U2 - 10.1586/14737140.2014.896207

DO - 10.1586/14737140.2014.896207

M3 - Article

C2 - 24605771

AN - SCOPUS:84896941352

SN - 1473-7140

VL - 14

SP - 367

EP - 379

JO - Expert review of anticancer therapy

JF - Expert review of anticancer therapy

IS - 4

ER -

Anti-angiogenic agent ramucirumab: Meaningful or marginal?

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this